Rejuvenation Technologies
CEO: John Ramunas
Rejuvenation’s ultimate goal is to extend the human healthspan. They are initially focused on diseases of aging with high unmet medical need. Rejuvenation uses TERT mRNA, which may have the potential to reverse years of telomere shortening, a major driver of aging and disease. In idiopathic pulmonary fibrosis, Rejuvenation’s first indication, the aim is to preserve lung function and reduce lung fibrosis, which would validate TERT mRNA as a platform technology with multiple potential clinical indications.